BPC-157 vs BPC 157 — Same Peptide, Different Names

The hyphen isn't a chemical marker. It's a formatting quirk. BPC-157 and BPC 157 refer to the exact same 15-amino-acid gastric pentadecapeptide, and whether a supplier writes it with or without a hyphen has zero bearing on the compound's molecular structure, mechanism of action, or research-grade purity. Yet the question persists across research communities, driven by the assumption that naming variations signal different compounds or formulation standards. They don't. The single most common source of confusion stems from inconsistent vendor labelling. Some peptide suppliers format the name with a hyphen (BPC-157), others drop it (BPC 157), and a few use legacy nomenclature like 'Body Protection Compound 157' without abbreviation. All three refer to the same peptide sequence derived from human gastric juice.

We've seen this confusion firsthand across research labs sourcing peptides for in vitro studies. The variation matters only for catalog search. Not for compound identity. The peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) remains identical regardless of how the name is hyphenated or abbreviated.

What's the difference between BPC-157 and BPC 157?

There is no chemical or functional difference between BPC-157 and BPC 157. Both names refer to the same 15-amino-acid sequence derived from human gastric juice, commonly studied for its role in tissue repair signalling. The hyphen is a stylistic choice, not a molecular distinction. The compound's mechanism. Upregulation of growth hormone receptor expression, modulation of nitric oxide pathways, and promotion of angiogenesis. Operates identically under both naming conventions.

The Featured Snippet Block answered the core question. The names are identical. What it didn't address is why the confusion persists and where it creates practical problems for researchers. The assumption that hyphenation signals a different formulation, salt form, or purity grade is widespread but incorrect. BPC-157 is not a 'modified version' of BPC 157, and vice versa. The peptide's functional activity, half-life (approximately four hours in circulation), and receptor-binding affinity remain unchanged. This article covers the origin of the naming variation, how to verify peptide identity beyond the label, what actually differentiates one BPC-157 product from another (purity testing, lyophilisation quality, and sterility verification), and how to source research-grade peptides with confidence.

The Origin of the Naming Variation

BPC-157 was first isolated and characterised by Croatian researchers in the early 1990s as a stable fragment of Body Protection Compound. A protein complex found in human gastric juice. The '157' designation refers to its position in the original compound sequence, and the hyphen was included in early academic publications to separate the acronym (BPC) from the numeric identifier. Over the following three decades, different research groups adopted different formatting conventions. Some retained the hyphen (BPC-157), others dropped it (BPC 157), and a smaller subset used the full name without abbreviation. None of these variations indicate a structural modification, alternate synthesis pathway, or proprietary formulation.

The peptide sequence itself. Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Is what defines the compound at a molecular level. The name is secondary. What complicates this further is that BPC-157 exists as both an acetate salt (the most common form in research settings) and a free peptide (rarely used due to lower stability). The salt form doesn't change the peptide sequence, but it does affect solubility and reconstitution behaviour. Some suppliers list 'BPC-157 Acetate' explicitly; others assume acetate as the default form and omit it from the label entirely. This is where naming confusion compounds into a procurement issue. Not because the hyphen matters, but because critical formulation details are sometimes unstated.

From our experience sourcing peptides for biological research, the most reliable approach is to verify the peptide's molecular weight (1419.53 Da for the free peptide, slightly higher for the acetate salt) and request a Certificate of Analysis (COA) with HPLC purity data. If a supplier cannot provide a COA or lists the peptide without specifying salt form or purity percentage, the naming convention is the least of your concerns. Product authenticity becomes the primary question.

What Actually Differentiates BPC-157 Products

The hyphen doesn't matter. What does: purity percentage (verified by HPLC), sterility testing (endotoxin levels below USP standards), lyophilisation quality (vial integrity, moisture content), and amino-acid sequencing verification. Two vials labelled 'BPC-157' from different suppliers can have radically different purity profiles. One might be 98.5% pure with confirmed sequence accuracy, the other 92% pure with detectable impurities from incomplete synthesis. The name tells you nothing about this.

Purity testing uses High-Performance Liquid Chromatography (HPLC) to measure the percentage of the target peptide versus byproducts, truncated sequences, and residual synthesis reagents. A research-grade BPC-157 product should demonstrate ≥98% purity by HPLC, with mass spectrometry data confirming the correct molecular weight and amino-acid sequence. Sterility verification ensures the lyophilised powder contains no bacterial endotoxins or viable microorganisms. Critical for any in vitro work involving cell culture or tissue models. Lyophilisation quality affects reconstitution reliability: poorly lyophilised peptides may not fully dissolve in bacteriostatic water, or may exhibit clumping that indicates structural degradation during freeze-drying.

At Real Peptides, every batch undergoes exact amino-acid sequencing and third-party HPLC verification before release. The naming format is irrelevant when the molecular identity is confirmed at every step. We've seen instances where vendors list 'BPC 157' with no hyphen, no COA, and no purity claim. In those cases, the lack of a hyphen isn't the red flag. The absence of verifiable testing is.

BPC-157 vs BPC 157: Product Comparison

This table compares how different naming conventions and sourcing standards impact what researchers actually receive. Same peptide sequence, vastly different reliability.

The clearest predictor of product reliability is not whether the name includes a hyphen. It's whether the supplier provides batch-specific HPLC data, lists the salt form explicitly, and uses small-batch synthesis with verified amino-acid sequencing. A vial labelled 'BPC 157' from a supplier with full COA transparency outperforms a vial labelled 'BPC-157' from a vendor with no testing documentation every time.

Key Takeaways

• BPC-157 and BPC 157 are the same 15-amino-acid peptide sequence. The hyphen is a formatting preference, not a molecular or functional distinction.
• The peptide's mechanism (growth hormone receptor upregulation, nitric oxide pathway modulation, angiogenesis promotion) operates identically under both naming conventions.
• Purity percentage (verified by HPLC), sterility testing, and amino-acid sequencing are what differentiate one BPC-157 product from another. Not the presence or absence of a hyphen.
• The acetate salt form (BPC-157 Acetate) is the most common formulation in research settings and offers superior solubility and storage stability compared to the free peptide.
• Reliable suppliers provide batch-specific Certificates of Analysis with HPLC purity data, mass spectrometry confirmation, and endotoxin testing. Naming format is secondary to verifiable testing.

What If: BPC-157 Scenarios

What If a Supplier Lists 'BPC 157' Without a Hyphen — Is It Less Pure?

No. The absence of a hyphen has no correlation with purity or quality. Request the Certificate of Analysis (COA). If the supplier provides HPLC purity data showing ≥98% purity with batch-specific testing, the naming format is irrelevant. The peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is what defines the compound, and naming conventions vary across suppliers without affecting molecular identity. What does matter: whether the supplier lists the salt form (acetate vs free peptide), provides third-party verification, and uses small-batch synthesis with exact amino-acid sequencing.

What If I See 'BPC-157 Acetate' and 'BPC-157' Listed Separately — Are They Different Compounds?

They're the same peptide, but the acetate designation specifies the salt form. Which affects solubility, reconstitution behaviour, and storage stability. BPC-157 Acetate is the acetate salt of the peptide, which dissolves more readily in bacteriostatic water and exhibits longer shelf life when stored at −20°C. The free peptide (listed simply as 'BPC-157' without salt form noted) is chemically identical in sequence but less stable over time. Most research-grade suppliers default to the acetate form unless otherwise specified. If the label doesn't clarify, ask before ordering.

What If a Peptide Labelled 'BPC-157' Doesn't Dissolve Fully After Reconstitution?

Incomplete dissolution signals one of three problems: incorrect reconstitution volume (too little bacteriostatic water), degraded lyophilisation (moisture exposure during storage), or low purity with insoluble byproducts from synthesis. The naming format isn't the cause. Properly lyophilised BPC-157 Acetate at ≥98% purity should dissolve completely within 30 seconds when reconstituted at the recommended concentration (typically 2mg peptide per 2mL bacteriostatic water). If clumping or visible particulates persist, contact the supplier for a replacement and request HPLC data for the affected batch. Incomplete dissolution is a quality control failure, not a naming issue.

The Blunt Truth About BPC-157 Naming

Here's the honest answer: the hyphen means nothing. Zero. The confusion exists because peptide suppliers use inconsistent labelling, and researchers assume naming variations signal different compounds or formulation grades. They don't. BPC-157 and BPC 157 are molecularly identical. Same 15-amino-acid sequence, same mechanism, same half-life, same receptor-binding behaviour. What differentiates one product from another is purity testing, sterility verification, and whether the supplier can prove the peptide's molecular identity with HPLC and mass spectrometry data. If you're spending time debating whether to source 'BPC-157' or 'BPC 157', you're asking the wrong question. Ask for the COA instead.

The peptide research space is flooded with vendors who list generic peptide names without supporting documentation. No HPLC data, no sterility confirmation, no amino-acid sequencing. In those cases, the presence or absence of a hyphen is cosmetic distraction from a larger authenticity problem. A supplier who provides batch-specific testing, lists the salt form explicitly, and uses small-batch synthesis with exact sequencing earns trust regardless of formatting preference. One who lists 'BPC 157' with no COA and no purity claim does not. Even if the name looks identical to a verified product.

The industry standard among research-grade suppliers is to include the hyphen (BPC-157) because it matches the format used in peer-reviewed publications and avoids ambiguity with other numbered peptides. But functional reliability comes from molecular verification. Not typographic consistency. If the peptide's molecular weight matches 1419.53 Da, HPLC confirms ≥98% purity, and the amino-acid sequence aligns with Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, you have authentic BPC-157 regardless of how the label is formatted. Anything less than that level of verification. Hyphen or no hyphen. Is guesswork.

The takeaway for researchers sourcing peptides: ignore the hyphen. Verify the molecule. Request the COA. Confirm the salt form. Check the purity percentage. Those are the variables that determine whether you're working with a reliable research tool or an unlabelled compound of uncertain identity. The name on the vial is secondary to the data that proves what's inside it.